Inozyme Pharma, Inc.
INZY · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$102,024 | -$71,169 | -$67,061 | -$56,624 |
| Dep. & Amort. | $742 | $833 | $744 | $674 |
| Deferred Tax | $0 | $0 | $0 | $170 |
| Stock-Based Comp. | $7,945 | $7,037 | $7,672 | $7,164 |
| Change in WC | $4,714 | -$3,082 | $2,012 | $85 |
| Other Non-Cash | -$3,284 | -$4,294 | -$1,128 | $378 |
| Operating Cash Flow | -$91,907 | -$70,675 | -$57,761 | -$48,153 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$62 | -$298 | -$410 | -$397 |
| Net Acquisitions | $0 | $0 | $5 | -$43 |
| Inv. Purchases | -$155,052 | -$269,330 | -$151,993 | -$121,967 |
| Inv. Sales/Matur. | $222,112 | $215,982 | $147,000 | $165,160 |
| Other Inv. Act. | $0 | $0 | -$5 | $43 |
| Investing Cash Flow | $66,998 | -$53,646 | -$5,403 | $42,796 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $0 | $40,000 | $4,050 | $0 |
| Stock Issued | $10,521 | $85,647 | $56,137 | $609 |
| Stock Repurch. | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | $877 | $322 | $12,601 | $609 |
| Financing Cash Flow | $11,398 | $125,969 | $72,788 | $609 |
| Forex Effect | $4 | -$18 | -$25 | $24 |
| Net Chg. in Cash | -$13,507 | $1,630 | $9,599 | -$4,724 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $34,899 | $33,269 | $23,670 | $28,394 |
| End Cash | $21,392 | $34,899 | $33,269 | $23,670 |
| Free Cash Flow | -$91,969 | -$70,973 | -$58,171 | -$48,550 |